RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Income Statement (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues
Product sales	$ 2,388.7	$ 2,695.0	$ 4,724.8	$ 4,821.1
Other revenues	31.5	37.4	67.0	81.4
Total revenues	2,420.2	2,732.4	4,791.8	4,902.5
Operating Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	647.3	669.9	1,267.5	1,177.8
Cost of other revenues	10.5	15.2	20.2	29.5
Selling, general and administrative	671.5	685.5	1,484.1	1,259.3
Research and development	124.3	81.1	227.4	136.9
Amortization and impairments of finite-lived intangible assets	887.6	585.4	1,582.1	950.6
Restructuring, integration and other costs	19.5	143.4	57.5	198.4
In-process research and development impairments and other charges	17.4	12.3	17.9	12.3
Acquisition-related costs	0.0	9.5	1.8	23.4
Acquisition-related contingent consideration	6.9	11.7	9.3	18.8
Other income (expense)	(45.3)	176.9	(22.7)	183.0
Total expenses	2,339.7	2,390.9	4,645.1	3,990.0
Operating income	80.5	341.5	146.7	912.5
Interest income	2.1	0.9	3.0	1.8
Interest expense	(472.5)	(412.7)	(899.1)	(710.5)
Loss on extinguishment of debt	0.0	0.0	0.0	(20.0)
Foreign exchange and other	13.1	5.6	6.9	(65.5)
(Loss) income before (recovery of) provision for income taxes	(376.8)	(64.7)	(742.5)	118.3
(Recovery of) provision for income taxes	(72.8)	(13.1)	(65.6)	71.4
Net (loss) income	(304.0)	(51.6)	(676.9)	46.9
Less: Net (loss) income attributable to noncontrolling interest	(1.7)	1.4	(0.9)	2.2
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ (302.3)	$ (53.0)	$ (676.0)	$ 44.7
Loss per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)	$ (0.88)	$ (0.15)	$ (1.96)	$ 0.13
Diluted (in usd per share)	$ (0.88)	$ (0.15)	$ (1.96)	$ 0.13
Weighted-average common shares outstanding (in millions)
Basic (in shares)	345.0	344.4	344.9	340.5
Diluted (in shares)	345.0	344.4	344.9	347.1
Revenue Recognition Correction
Revenues
Product sales				$ 4,821.1
Other revenues				81.4
Total revenues				4,902.5
Operating Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)				1,177.8
Cost of other revenues				29.5
Selling, general and administrative				1,259.3
Research and development				136.9
Amortization and impairments of finite-lived intangible assets				950.6
Restructuring, integration and other costs				198.4
In-process research and development impairments and other charges				12.3
Acquisition-related costs				23.4
Acquisition-related contingent consideration				18.8
Other income (expense)				183.0
Total expenses				3,990.0
Operating income				912.5
Interest income				1.8
Interest expense				(710.5)
Loss on extinguishment of debt				(20.0)
Foreign exchange and other				(65.5)
(Loss) income before (recovery of) provision for income taxes				118.3
(Recovery of) provision for income taxes				71.4
Net (loss) income				46.9
Less: Net (loss) income attributable to noncontrolling interest				2.2
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.				$ 44.7
Loss per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)				$ 0.13
Diluted (in usd per share)				$ 0.13
Weighted-average common shares outstanding (in millions)
Basic (in shares)				340.5
Diluted (in shares)				347.1
Revenue Recognition Correction | Amounts Recognized as of Acquisition Date (as previously reported)
Revenues
Product sales				$ 4,841.9
Other revenues				81.4
Total revenues				4,923.3
Operating Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)				1,230.3
Cost of other revenues				29.5
Selling, general and administrative				1,259.3
Research and development				136.9
Amortization and impairments of finite-lived intangible assets				950.6
Restructuring, integration and other costs				198.4
In-process research and development impairments and other charges				12.3
Acquisition-related costs				19.3
Acquisition-related contingent consideration				18.8
Other income (expense)				183.0
Total expenses				4,038.4
Operating income				884.9
Interest income				1.8
Interest expense				(710.5)
Loss on extinguishment of debt				(20.0)
Foreign exchange and other				(65.5)
(Loss) income before (recovery of) provision for income taxes				90.7
(Recovery of) provision for income taxes				67.8
Net (loss) income				22.9
Less: Net (loss) income attributable to noncontrolling interest				2.2
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.				$ 20.7
Loss per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)				$ 0.06
Diluted (in usd per share)				$ 0.06
Weighted-average common shares outstanding (in millions)
Basic (in shares)				340.5
Diluted (in shares)				347.1
Revenue Recognition Correction | Restatement Adjustment
Revenues
Product sales				$ (20.8)
Other revenues				0.0
Total revenues				(20.8)
Operating Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)				(52.5)
Cost of other revenues				0.0
Selling, general and administrative				0.0
Research and development				0.0
Amortization and impairments of finite-lived intangible assets				0.0
Restructuring, integration and other costs				0.0
In-process research and development impairments and other charges				0.0
Acquisition-related costs				4.1
Acquisition-related contingent consideration				0.0
Other income (expense)				0.0
Total expenses				(48.4)
Operating income				27.6
Interest income				0.0
Interest expense				0.0
Loss on extinguishment of debt				0.0
Foreign exchange and other				0.0
(Loss) income before (recovery of) provision for income taxes				27.6
(Recovery of) provision for income taxes				3.6
Net (loss) income				24.0
Less: Net (loss) income attributable to noncontrolling interest				0.0
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.				$ 24.0
Loss per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)				$ 0.07
Diluted (in usd per share)				$ 0.07